PVLA (Palvella Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PVLA Palvella Therapeutics Inc PVLA
14 GF Score
Price $137.66
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Net Margin %?

Palvella Therapeutics PVLA -3.45% 14 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates PVLA with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Palvella Therapeutics ranks worse than 106157.01% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Palvella Therapeutics's Net Income for the three months ended in Mar. 2026 was $-15.77 Mil. Palvella Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Palvella Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Palvella Therapeutics's Net Margin % or its related term are showing as below:


PVLA's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.445
* Ranked among companies with meaningful Net Margin % only.

Palvella Therapeutics  (NAS:PVLA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Palvella Therapeutics Net Margin % Related Terms

Palvella Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Net Margin % Chart

Palvella Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 0.00 0.00 0.00

Palvella Therapeutics Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PVLA vs GENB, NKTR, SLBT: Net Margin % Comparison

For the Biotechnology subindustry, Palvella Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Palvella Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palvella Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Palvella Therapeutics's Net Margin % falls into.


PVLA
14GF Score
Palvella Therapeutics Inc PVLA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Palvella Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-41.715/0
= %

Palvella Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-15.767/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Palvella Therapeutics (PVLA) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Palvella Therapeutics and its competitors. According to the industry distribution chart, Palvella Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry.
Is Palvella Therapeutics' Net Margin % too high?
Palvella Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Palvella Therapeutics ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Palvella Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Net Margin % compare to GENB and NKTR?
According to the Biotechnology industry distribution chart, Palvella Therapeutics ranks #999999 out of 942 companies for Net Margin %. This places Palvella Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (PVLA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Palvella Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Palvella Therapeutics (PVLA), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PI6:Germany
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
14GF Score

Get the complete analysis for PVLA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$137.66
Price